Objective: To study the results after fractionated radiotherapy of large arteriovenous malformations (AVMs).

Methods: Twenty-eight patients harboring large AVMs were treated between 1980 and 1985 with fractionated radiotherapy with up to 3.5 Gy per fraction twice a week to a total dose of 41 to 50 Gy. All but 5 patients were examined with an angiogram at least 4 years after the treatment.

Results: Two AVMs (8%) were obliterated after the treatment. Eight patients died: five as a result of hemorrhages, two of unknown causes, and one as a result of lung carcinoma. Five patients deteriorated slightly, three moderately, and four severely after the treatment. The longer the observation time, the higher the incidence of neurological deterioration. The AVMs were significantly larger in the four patients who developed a severe deficit after the treatment. The annual hemorrhage rate was 6% after the treatment, suggesting that radiation did not protect from hemorrhage unless the AVM was occluded. AVMs with a pretreatment rupture had a annual hemorrhage rate of 12%, compared with 1% in the unruptured cases.

Conclusion: The obliteration rate after fractionated radiotherapy with a dose per fraction of 2 to 4 Gy to a total dose of up to 50 Gy was low. The clinical outcome suggests that the radiation treatment may have caused significant side effects. Although the risk for hemorrhage in previously ruptured large AVMs is high, the use of fractionated radiotherapy using low doses per fraction cannot be recommended.

Download full-text PDF

Source
http://dx.doi.org/10.1227/01.neu.0000163095.56638.26DOI Listing

Publication Analysis

Top Keywords

fractionated radiotherapy
16
arteriovenous malformations
8
large avms
8
total dose
8
annual hemorrhage
8
hemorrhage rate
8
patients
5
avms
5
treatment
5
long-term fractionated
4

Similar Publications

Purpose: High-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy (EBRT) is an effective treatment for patients with high- and very-high-risk prostate cancer. We sought to identify the factors associated with reduced biochemical recurrence rates following HDR-BT.

Methods: A total of 304 patients with high- or very-high-risk prostate cancer who underwent HDR-BT and EBRT were analyzed.

View Article and Find Full Text PDF

Dose Recommendations for Prostrate-specific Membrane Antigen Positron Emission Tomography (PSMA PET) Guided Boost Irradiation to Lymphatic Tissue in Prostate Adenocarcinoma.

Clin Oncol (R Coll Radiol)

December 2024

Alberta Health Services, South Zone, Lethbridge, AB, Canada; University of Calgary, Department of Oncology, Calgary, AB, Canada; University of Calgary, Department of Physics and Astronomy, Calgary, AB, Canada.

Aims: Prostrate-specific membrane antigen positron emission tomography (PSMA-PET) imaging has led to an increase in identifiable small volume metastatic disease in prostate adenocarcinoma. There is clinical equipoise in how to treat these using radiotherapy regimens. The aim of this study is to determine an adequate dosing regimen for small volume lymphatic metastases in prostate adenocarcinoma.

View Article and Find Full Text PDF

Background: Proton therapy (PRT) is an innovative radiotherapeutic modality for the treatment of cancer with unique ballistic properties. The depth-dose distribution of a proton beam reduces exposure of healthy tissues to radiations, compared with photon-therapy (XRT). To date, only few indications for proton-therapy, like pediatric cancers, chordomas, or intra-ocular neoplasms, are reimbursed by Health systems.

View Article and Find Full Text PDF

Intrafraction Patient Positional Uncertainty in Lung Stereotactic Ablative Radiotherapy with Abdominal Compression.

Pract Radiat Oncol

December 2024

Department of Radiation Oncology, Willis Knighton Cancer Center, 2600 Kings Highway, Shreveport, Louisiana, USA 71103 &, Department of Clinical Research, University of Jamestown, Fargo, ND, USA. Electronic address:

Purpose: Motion management presents a significant challenge in thoracic stereotactic ablative radiotherapy (SABR). Currently, a 5.0 mm standard planning target volume (PTV) margin is widely used to ensure adequate dose to the tumor.

View Article and Find Full Text PDF

Technical Aspects of a National Service for Paediatric Pelvic Brachytherapy.

Clin Oncol (R Coll Radiol)

December 2024

Department of Oncology, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London, NW1 2PG, UK. Electronic address:

Aims: Brachytherapy is advantageous for localised rhabdomyosarcomas in children compared with external beam radiotherapy, sparing close organs at risk with highly conformal dosimetry. A methodology for planning and delivering fractionated high-dose-rate paediatric pelvic brachytherapy is detailed, and the dosimetric parameters are presented. This provides a practical template for radiotherapy departments with a similar patient cohort to implement this treatment technique.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!